UB Paderborn / Katalog / Suche / in CDI

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Annals of oncology, 2018-11, Vol.29 (11), p.2240-2246

2018

Link zum Volltext

Verfügbarkeit prüfen

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Annals of oncology, 2014-01, Vol.25 (1), p.107-116

2014

Link zum Volltext

Verfügbarkeit prüfen

Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity

Neuroscience, 2009-03, Vol.159 (3), p.1154-1163

2009

Link zum Volltext

Verfügbarkeit prüfen

P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer

Journal of thoracic oncology, 2019-11, Vol.14 (11), p.S1191-S1192

2019

Link zum Volltext

Verfügbarkeit prüfen

Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly

European journal of cancer care, 2016-09, Vol.25 (5), p.753-763

2016

Link zum Volltext

Verfügbarkeit prüfen

2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC)

European journal of cancer (1990), 2015-09, Vol.51, p.S369-S370

2015

Link zum Volltext

Verfügbarkeit prüfen

2112 Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI + cetuximab once every 2 weeks in the APEC study

European journal of cancer (1990), 2015-09, Vol.51, p.S367-S367

2015

Link zum Volltext

Verfügbarkeit prüfen

67. The AMP-kinase inhibitor metformin inhibits chemotherapy-induced peripheral neuropathy

Brain, behavior, and immunity, 2014-09, Vol.40, p.e20-e20

2014

Link zum Volltext

Verfügbarkeit prüfen

The RNA binding and transport proteins staufen and fragile X mental retardation protein are expressed by rat primary afferent neurons and localize to peripheral and central axons

Neuroscience, 2006-01, Vol.141 (4), p.2107-2116

2006

Link zum Volltext

Verfügbarkeit prüfen

The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat

Neuroscience, 2003-01, Vol.120 (1), p.155-162

2003

Link zum Volltext

Verfügbarkeit prüfen

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

The New England journal of medicine, 2021-06, Vol.384 (25), p.2371-2381

2021

Link zum Volltext

Verfügbarkeit prüfen

403P First-line anti-EGFR therapy, patient characteristics and survival: Results from South Australian (SA) metastatic colorectal registry (mCRCR)

Annals of oncology, 2022-09, Vol.33, p.S721

2022

Link zum Volltext

Verfügbarkeit prüfen

Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research

Annals of oncology, 2014-08, Vol.25 (8), p.1506-1516

2014

Link zum Volltext

Verfügbarkeit prüfen

1528P Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer

Annals of oncology, 2020-09, Vol.31, p.S941-S941

2020

Link zum Volltext

Verfügbarkeit prüfen

586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Annals of oncology, 2023-10, Vol.34, p.S426-S427

2023

Link zum Volltext

Verfügbarkeit prüfen

1106P Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms

Annals of oncology, 2021-09, Vol.32, p.S913-S913

2021

Link zum Volltext

Verfügbarkeit prüfen

435P The AGITG Modulate study: Randomised phase II study testing manipulation of the tumour micro environment (TME) to enable synergy with PD1 inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

Annals of oncology, 2021-09, Vol.32, p.S552-S552

2021

Link zum Volltext

Verfügbarkeit prüfen

131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886

Annals of oncology, 2022-11, Vol.33, p.S1483-S1483

2022

Link zum Volltext

Verfügbarkeit prüfen

83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial

Annals of oncology, 2020-11, Vol.31, p.S1274-S1275

2020

Link zum Volltext

Verfügbarkeit prüfen

107P Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study

Annals of oncology, 2020-11, Vol.31, p.S1283-S1283

2020

Link zum Volltext

Verfügbarkeit prüfen

Structure-microwave property relations of Ca and Sr titanates

Journal of the European Ceramic Society, 2001, Vol.21 (15), p.2629-2632

2001

Link zum Volltext

Verfügbarkeit prüfen

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C

Annals of oncology, 2012-06, Vol.23 (6), p.1531-1536

2012

Link zum Volltext

Verfügbarkeit prüfen

85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)

Annals of oncology, 2020-11, Vol.31, p.S1276-S1276

2020

Link zum Volltext

Verfügbarkeit prüfen

Numerical and experimental characterization of a family of two–roll–mill flows

Proceedings of the Royal Society. A, Mathematical, physical, and engineering sciences, 2003-01, Vol.459 (2029), p.117-135

2003

Link zum Volltext

Verfügbarkeit prüfen

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines

Annals of oncology, 2014-01, Vol.25 (1), p.117-121

2014

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial

Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

Cannabinoid CB1 receptors are expressed in the mouse urinary bladder and their activation modulates afferent bladder activity

P2.15-C Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer

Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly

2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC)

2112 Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI + cetuximab once every 2 weeks in the APEC study

67. The AMP-kinase inhibitor metformin inhibits chemotherapy-induced peripheral neuropathy

The RNA binding and transport proteins staufen and fragile X mental retardation protein are expressed by rat primary afferent neurons and localize to peripheral and central axons

The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat

Sotorasib for Lung Cancers with KRAS p.G12C Mutation

403P First-line anti-EGFR therapy, patient characteristics and survival: Results from South Australian (SA) metastatic colorectal registry (mCRCR)

Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research

1528P Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer

586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

1106P Phase I study of hepatic intralesional rose bengal disodium (PV10), an autolytic immunotherapy, in metastatic neuroendocrine neoplasms

435P The AGITG Modulate study: Randomised phase II study testing manipulation of the tumour micro environment (TME) to enable synergy with PD1 inhibitors in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

131TiP ASCEND: Randomized, double-blinded phase II study of gemcitabine and nab-paclitaxel with CEND-1 or placebo in untreated metastatic pancreatic ductal adenocarcinoma - An Australasian Gastro-Intestinal Trials Group (AGITG) trial ACTRN12621001290886

83MO AMG 510, a novel small molecule inhibitor of KRAS(G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 phase I trial

107P Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study

Structure-microwave property relations of Ca and Sr titanates

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C

85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study)

Numerical and experimental characterization of a family of two–roll–mill flows

Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines

Suchergebnisse filtern